Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05842824
NCT05842824
Not yet recruiting
Not Applicable

An Observational Study of Patients With Autoimmune Disease

Target PharmaSolutions, Inc.0 sites500,000 target enrollmentMarch 31, 2025
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAutoimmune Diseases

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autoimmune Diseases
Sponsor
Target PharmaSolutions, Inc.
Enrollment
500000
Primary Endpoint
To characterize the natural history of disease in patients with autoimmune disease of various etiologies.
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

TARGET-AUTOIMMUNE is an observational research study to conduct a comprehensive review of outcomes for patients with autoimmune and related diseases. .

Registry
clinicaltrials.gov
Start Date
March 31, 2025
End Date
December 31, 2038
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Adult patients at the time of enrollment with a diagnosis autoimmune disease by select ICD-10 codes in the EHR interface

Exclusion Criteria

  • •Manual removal (sponsor or site request)
  • •No EHR interface encounter \> 3 years
  • •Engaged Cohort
  • •Inclusion Criteria:
  • •Adult patients diagnosed and managed for these conditions invited to participate
  • •Ability to provide written informed consent
  • •Exclusion Criteria:
  • •Patient expressed desire to withdraw consent to complete PROs
  • •Failure to complete PROs within 24 weeks of initial invitation
  • •Greater than 24 months lapse of survey completion after baseline surveys completed

Outcomes

Primary Outcomes

To characterize the natural history of disease in patients with autoimmune disease of various etiologies.

Time Frame: 15 Years

To assess safety and effectiveness of autoimmune disease treatments and treatments for complications of any related conditions

Time Frame: 20 Years

Secondary Outcomes

  • To select and evaluate quality of care measures for patients with autoimmune diseases(15 Years)
  • To evaluate provider management practices in the treatment of patients with autoimmune diseases(15 Years)
  • To evaluate longitudinal and patient reported outcomes in patients with autoimmune diseases(15 Years)

Similar Trials

Recruiting
Not Applicable
Autoimmune Hepatitis Cohort in ChinaAutoimmune Hepatitis
NCT05785793Shanghai Jiao Tong University School of Medicine1,000
Not yet recruiting
Not Applicable
An Observational Study of Patients With Metabolic Syndrome and Related ConditionsMetabolic Syndrome
NCT05842811Target PharmaSolutions, Inc.2,000,000
Recruiting
Not Applicable
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile DermatomyositisAutoinflammatory DiseaseJuvenile Dermatomyositis
NCT00059748National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)5,000
Not yet recruiting
Not Applicable
A Study on Factors of Biochemical Response in Autoimmune HepatitisAutoimmune Hepatitis
NCT06356506Beijing Friendship Hospital630
Not yet recruiting
Not Applicable
An Observational Study of Patients Living With Chronic Neurological DiseasesNeurological Diseases or ConditionsDementia of Alzheimer TypeAlzheimer DiseaseMild Cognitive ImpairmentParkinson DiseaseMultiple Sclerosis
NCT05796037Target PharmaSolutions, Inc.1,500,000